Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab1800 vs Keytruda in Adjuvant Melanoma
NCT07581509Phase 1Recruiting
- Sponsor
- Mylan
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pembrolizumab in melanoma (2 arms), sponsored by Mylan. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to 21 Days and Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State at 21 weeks. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07581509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581509.